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INTRODUCTION
The prevalence of hepatitis C virus (HCV) infection in Mongolia 
is estimated to be 15.6% based on a national seroepidemiologic 
data.1-3 Such a high rate of HCV infection in Mongolia might be 
due to reuse of needles before 1990, traditional medicine includ-
ing bloodletting, and other unsafe medical or dental procedures. 
Interestingly, the most common HCV genotype in Mongolia was 
found to be 1b, accounting for 98% of all genotypes.2
Since the introduction of direct-acting antivirals (DAAs) includ-
Background/Aims: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 
1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients.
Methods: Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were 
treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) 
with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. HCV RNA was 
measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), 
and sustained virologic response at 12 weeks after end of treatment (SVR12).
Results: Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a 
showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between 
patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6×106 IU/mL (n=866; 17.2%), or 
liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) 
were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 
9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%).
Conclusions: LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The 
real-world data might be applicable to patients in other Asian-Pacific countries. (Clin Mol Hepatol 2021;27:125-135)
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Study Highlights
We investigated the high efficacy and safety of ledipasvir/sofosbuvir regimen in real-world Mongolian patients with genotype 1 hepatitis C virus, es-
pecially in patients with genotype 1b. Although LDV/SOF treatment is not a novel issue, this large-scale cohort study was aimed to show the efficacy 
and safety of an affordable treatment for developing countries such as Mongolia. This study could be a good example of successful hepatitis C treat-
ment practice in developing countries where healthcare budgets are limited.
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ing boceprevir and telaprevir in 2011, the new DAA ledipasvir/so-
fosbuvir (LDV/SOF) in 2014 opened a new era of interferon-free, 
all-oral agents for HCV treatment.4 A fixed dose of ledipasvir, a 
NS5A inhibitor, and sofosbuvir, a nucleotide analogue NS5B poly-
merase inhibitor, showed a promising antiviral efficacy and safety 
in genotype 1 HCV-infected patients. In a phase 3 pivotal study, 
the overall sustained virologic response (SVR) rates were 99% in 
treatment-naïve patients who received 12 weeks of LDV/SOF.5 
Moreover, in genotype 1 HCV patients who had experienced prior 
interferon-based treatment, 12 weeks of LDV/SOF plus ribavirin 
resulted in 96% of SVR rates.6
In the era of interferon or pegylated interferon (PEG-IFN), Mon-
golian patients rarely underwent antiviral therapy because the 
cost was high and the access to medical resources was signifi-
cantly limited. However, according to the approval of the imple-
mentation of the Hepatitis Prevention, Control and Elimination 
Program between 2016 and 2020 by the Mongolian government, 
treatment campaign for HCV started from January 2016. Fortu-
nately, Gilead Sciences, Inc. has successfully implemented an ac-
cess program, in which the cost of LDV/SOF was remarkably re-
duced to 300 US dollars per bottle. To date, more than 10,000 
Mongolian patients infected with HCV have received brand LDV/
SOF (Harvoni®; Gilead Sciences, Inc., Foster City, CA, USA).
There have been few real-life data regarding brand or generic 
LDV/SOF for HCV patients worldwide.7 However, the sample size 
was small. Thus, the aim of this study was to report the efficacy 
and safety of brand LDV/SOF in 5,028 Mongolian patients infect-
ed with genotype 1 HCV who received LDV/SOF or LDV/SOF plus 
ribavirin for 12 weeks.
PATIENTS AND METHODS
Patients eligibility
In this retrospective cohort study, patients who met the follow-
ing criteria were included: 1) patients aged 18–70 years; 2) pa-
tients with chronic HCV infection documented by anti-HCV or by 
patient’s statement; 3) patients with HCV genotype 1a or 1b; 
4) treatment-experienced or -naïve patients; 5) patients with neg-
ative results for hepatitis A and B as well as human immunodefi-
ciency virus (HIV); 6) patients without decompensation of liver 
function, such as ascites and hepatic encephalopathy; 7) patients 
without diagnosis of hepatocellular carcinoma at enrollment; 
8) patients with normal value of baseline serum alpha-fetoprotein; 
9) patients with normal range of baseline serum creatinine; 
10) patients who have completed follow-up for 12 weeks after 
the end of treatment (EOT); and 11) patients who were treated 
with only brand LDV/SOF.
Laboratory tests and data collection
All included patients were subjected to laboratory tests at the 
beginning of treatment, including complete blood count (CBC), al-
anine aminotransferase (ALT), aspartate aminotransferase (AST), 
total bilirubin, serum albumin, prothrombin time, IgG anti-hepati-
tis A virus, hepatitis B virus surface antigen, anti-HIV, and anti-
HCV. Anti-HCV reactivity was assayed using a HISCL 5000 ana-
lyzer (Sysmex Corp., Kobe, Japan), and serum HCV RNA was 
quantitated using a Roche COBAS®TagMan HCV Test (V3.0, cut-
off value, 15 IU/mL; Roche Molecular Systems, Branchburg, NJ, 
USA). HCV genotyping was performed using a gene sequencing 
assay.
Laboratory tests, including CBC, ALT, AST, total bilirubin, serum 
albumin, prothrombin time, and serum HCV RNA quantitation, 
were repeated at 4 weeks, EOT, and 12 weeks after EOT.
Figure 1. Flowchart of patient enrollment. HCV, hepatitis C virus; LDV/
SOF, ledipasvir/sofosbuvir.
Approximately 65,000 patients infected with HCV received  
LDV/SOF between 2016 and 2020 by treatment campaign  
in Mongolia
5,449 patients received brand LDV/SOF (Harvoni®; Gilead 
Science, Inc., CA, USA) between 2016 and 2020 and 
completed follow-up for 12 weeks after the end of treatment
5,093 Mongolian patients were selected for review
Finally, 5,028 patients were retrospectively reviewed
65 patients with genotype 2 HCV were excluded
356 patients were excluded
• 300 patients were too old (age >70)
• 5 patients had decompensated liver function
• 3 patients were diagnosed with hepatocellular carcinoma
• 33 patients had other comorbidities
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Ultrasonographic evaluation and liver stiffness 
measurement
Before administration of LDV/SOF, baseline ultrasonographic ex-
amination and liver stiffness measurement (LSM) using transient 
elastography (FibroScan®, Echosens, Paris, France) were conduct-
ed. LSM was performed by a single experienced technician who 
was blinded to the patient information. The results were ex-
pressed as kilopascals (kPa), and the interquartile range (IQR) was 
defined as an index of intrinsic variability of LSM corresponding to 
the interval of LSM results containing 50% of the valid measure-
ments between the 25th and 75th percentiles. The median value 
was considered representative of the elastic modulus of the liver. 
Only procedures with at least 10 valid measurements, a success 
rate of at least 60%, and an IQR to median value ratio of 30% 
were considered reliable.8-10 The cutoff value was considered as 
8.4 kPa for F2, 9.6 kPa for F3, and 12.8 kPa for F4 fibrosis accord-
ing to a recent study.11 Because patients were subjected to LSM at 
baseline with active inflammation, overassessment of LSM could 
occur. Therefore, in this study, nodular liver surface combined 
with blunted edge in ultrasonographic evaluation and high liver 
stiffness (LS) value (>12.5 kPa) was considered as a relative defi-
nition of liver cirrhosis.12
Because repeated transient elastography was not feasible in 
Mongolia, AST to platelet ratio index (APRI; APRI = AST / 41 [as 
the upper limit of normal AST] / platelet count) and fibrosis-4 
(FIB-4) index (FIB-4 index = age × AST / [platelet count × ALT1/2]), 
which are simple non-invasive fibrosis scoring systems, were cal-
culated at each time point during treatment. Cutoff of significant 
and severe fibrosis were considered as 0.7 and 1.0 in APRI, and 
1.45 and 3.25 in FIB-4, respectively.11,13
Antiviral therapy
Patients with genotype 1a or 1b received a fixed-dose combina-
tion tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 
12 weeks, as only 12-week regimen was approved in Mongolia. If 
patients had a prior experience of PEG-IFN treatment for HCV, 
they received an additional fixed dose of 1,000 mg ribavirin dur-
ing LDV/SOF treatment.5,6,14
Assessment of antiviral efficacy and safety
The primary efficacy endpoint was SVR, defined as undetect-
able HCV RNA at 12 weeks after EOT (SVR12). Rapid virologic re-
sponse (RVR) and EOT response (ETR) were defined as completely 
undetectable HCV RNA at 4 weeks and EOT, respectively. The vi-
rologic relapse was defined as a detectable HCV RNA level after 
EOT in a patient who had undetectable HCV RNA during treat-
ment. Non-response was defined as a detectable HCV RNA at 
EOT in a patient who did not experience virologic breakthrough. 
Any adverse events (AEs) that developed during antiviral therapy 
were recorded.
Statistical analysis
Continuous variables were expressed as median and IQR. Cate-
gorical variables were presented by frequency and percentage. 
Figure 2. Rates of RVR, ETR, and SVR12. IFN, interferon; HCV, hepatitis C virus; LSM, liver stiffness measurement; RVR, rapid virological response; ETR, 
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Figure 3. Estimated marginal mean changes in laboratory test results 
and non-invasive fibrosis index after ledipasvir/sofosbuvir treatment: (A) 
aspartate aminotransferase (AST), (B) alanine aminotransferase (ALT), (C) 
total bilirubin, (D) serum albumin, (E) platelet count, (F) AST to platelet 
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Differences between continuous and categorical variables were 
examined for statistical significance using Student’s t-test (or the 
Mann-Whitney test, as appropriate) and the chi-squared test (or 
Fisher’s exact test, as appropriate). A generalized linear model us-
ing repeated measured analysis of variance (ANOVA) was used to 
assess the longitudinal changes in variables with a Bonferroni 
correction for multiple comparisons. Multivariate analysis was 
performed with adjustments for significant variables with P<0.05 
in the univariate analyses using logistic regression model. Contin-
uous variables were categorized using cutoffs that were clinically 
used or obtained with reference to the receiver operating charac-
teristic (ROC) curve, and entered into the univariate and multivari-
ate analyses. The odds ratio (OR) for SVR12 and its 95% confi-
dence interval (CI) were calculated for each selected variable. All 
statistical analyses were performed using the Statistical Package 
for Social Sciences (SPSS version 25.0; IBM, Armonk, NY, USA). A 
P value <0.05 was considered statistically significant.
RESULTS
Baseline characteristics and on-treatment laboratory 
tests
According to the Hepatitis Prevention, Control and Elimination 
Program of the Mongolian government from January 2016, there 
were more than 10,000 patients treated with brand LDV/SOF for 
genotype 1 HCV between December 2015 and June 2019, and 
5,449 patients completed follow-up for 12 weeks after the EOT. 
After excluding 421 patients, 5,028 patients who met the inclu-
sion criteria were retrospectively analyzed (Fig. 1).
Baseline characteristics and on-treatment laboratory tests of the 
5,028 patients are described in Table 1 and Supplementary Table 
1. The median age was 54.0 years (IQR, 45.0–62.0). The propor-
tion of male patients was 46.2% (n=2,324). Liver cirrhosis was 
clinically diagnosed in 1,151 patients (22.9%). Additional ribavirin 
was administered during LDV/SOF treatment in only 81 (1.6%) 
genotype 1b patients who had previous PEG-IFN experience. The 
median AST and ALT levels were slightly high (50.5 and 63.8 IU/L) 
at baseline. The median baseline LS value was 8.0 kPa (IQR, 5.4–
11.7), and 1,721 patients (34.2%) showed LS value >9.6 kPa.
Almost all (n=5,005; 99.5%) patients had HCV genotype 1b. 
Between genotype 1a and 1b, there was no significant difference 
at baseline regardless of sex distribution (69.6% vs. 46.1% of 
male sex, P=0.027), body mass index (median 29.1 vs. 28.2 kg/m2, 
P=0.019), and FIB-4 index (median 2.58 vs. 1.76, P=0.037). At 
4 weeks, genotype 1a patients showed slightly low serum albu-
min level (median 4.0 vs. 4.2 g/dL) as well as high prevalence of 
APRI above 1.0 (21.7% vs. 5.8%) and FIB-4 above 3.25 (21.7% 
vs. 6.9%) (all P<0.05).
PEG-IFN-experienced patients tended to have higher baseline 
HCV RNA (log value 6.06 vs. 5.68, P=0.002). However, other 
variables were not significantly different between patients with or 
without PEG-IFN experience.
Treatment outcomes
Of total 5,028 patients with HCV genotype 1 infection, 5,008 
(99.6%) had successful HCV disappearance after 12 weeks of an-
tiviral therapy. RVR, ETR, and SVR12 were analyzed in 4,825 
(96.0%), 5,008 (99.6%), and 5,008 patients (99.6%). All patients 
who showed RVR achieved ETR later, and patients who achieved 
ETR finally reached SVR12 without virologic relapse. RVR, ETR, 
and SVR12 were achieved by 69.6% (n=16), 69.6%, and 69.6% 
of 23 patients with genotype 1a, respectively. In contrast, the 
rates of RVR, ETR, and SVR12 in 5,005 patients with genotype 1b 
were 96.1% (n=4,809), 99.7% (n=4,992), and 99.7%, respec-
tively. Most patients showed ETR and RVR regardless of the 
presence of PEG-IFN experience, high baseline HCV RNA 
(>6×106 IU/mL), liver cirrhosis or indicators of advanced fibrosis 
including high LS, APRI, and FIB-4 values (Fig. 2, Supplementary 
Table 2).
Figure 4. Estimated mean changes in log value of HCV RNA after treat-
ment in 20 patients who failed to achieve end-treatment response and 













Baseline 4 weeks End of 
treatment
HCV RNA quanititation (log IU/mL)
24 weeks
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Laboratory result changes during antiviral therapy
Changes in the estimated marginal mean of laboratory test re-
sults during antiviral therapy are described in Figure 3 and Sup-
plementary Table 3. The estimated mean values of baseline AST 
and ALT levels were 68.9±0.7 and 85.0±0.3 IU/L, significantly 
decreased to 32.3±0.3 and 36.5±0.4 IU/L at 4 weeks, and fur-
ther decreased to 29.2±0.2 and 32.7±0.2 IU/L at EOT, respective-
ly (all P<0.001). The estimated mean value of total bilirubin also 
decreased (0.96 to 0.78 mg/dL, P<0.001), and the mean serum 
albumin was slightly elevated (4.2 to 4.3 g/dL, P<0.001) during 
antiviral therapy. Platelet count tended to slightly decrease, but 
almost similar (200.8/mm3 to 196.8/mm3, P<0.001). The estimat-
ed mean values of APRI and FIB-4 also reliably decreased (1.01 to 
0.41 and 2.35 to 1.57, respectively; all P<0.001).
Virologic breakthrough after non-response
Estimated mean HCV RNA quantitation in 20 patients (0.4%) 
who showed non-response decreased until the EOT (5.97±0.28 to 
3.39±0.08 log IU/mL, P<0.001). However, at 12 weeks after the 
EOT, the log value of HCV RNA in non-responders was elevated 
to 4.79±0.14 (P<0.001), which corresponded to virologic relapse 
after incomplete virologic response (Fig. 4, Supplementary Table 4).
Table 2. Multivariate analysis for complete end-treatment response and sustained virologic response at 12 weeks after treatment
Variable Univariate P-value
Multivariate analysis
P-value OR (95% CI)
At baseline
HCV RNA >1,120,000 IU/mL 0.077 0.078 0.446 (0.182–1.094)
Liver cirrhosis 0.077 0.808 0.847 (0.222–3.232)
LS value* >9.6 kPa 0.058 0.324 0.517 (0.139–1.919)
Baseline FIB-4 >3.25 0.014 0.025 0.356 (0.144–0.881)
At 4 weeks, APRI >0.7
Liver cirrhosis 0.077 0.105 0.474 (0.192–1.169)
HCV RNA at baseline >1,120,000 IU/mL 0.077 0.074 0.441 (0.180–1.084)
Bilirubin >2.0 mg/dL 0.001 0.999 Too high
Albumin <3.5 g/dL 0.020 0.024 0.278 (0.092–0.845)
Platelet count <150 /mm3 0.042 0.600 0.762 (0.275–2.109)
APRI >0.7 <0.001 0.007 0.248 (0.090–0.688)
At 4 weeks, APRI >1.0
Liver cirrhosis 0.077 0.127 0.494 (0.199–1.223)
HCV RNA at baseline >1,120,000 IU/mL 0.077 0.086 0.455 (0.185–1.119)
Bilirubin >2.0 mg/dL 0.001 0.999 Too high
Albumin <3.5 g/dL 0.020 0.032 0.295 (0.097–0.898)
Platelet count <150 /mm3 0.042 0.245 0.566 (0.217–1.478)
APRI >1.0 0.001 0.027 0.283 (0.093–0.864)
At 4 weeks, FIB-4 >3.25
Liver cirrhosis 0.077 0.114 0.482 (0.195–1.190)
HCV RNA at baseline >1,120,000 IU/mL 0.077 0.920 0.462 (0.188–1.136)
Bilirubin >2.0 mg/dL 0.001 0.999 Too high
Albumin <3.5 g/dL 0.020 0.046 0.318 (0.103–0.981)
Platelet count <150 /mm3 0.042 0.446 0.669 (0.238–1.883)
FIB-4 >3.25 <0.001 0.022 0.263 (0.084–0.824)
OR, odds ratio; CI, confidence interval; HCV, hepatitis C virus; LS, liver stiffness; FIB-4, fibrosis-4; APRI, aspartate aminotransferase to platelet ratio index.
*Measured by transient elastography.
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Variables associated to ETR and SVR12
In univariate analysis, variables at baseline, such as the pres-
ence of liver cirrhosis, high HCV RNA (>1.12×106 IU/mL, cutoff by 
ROC curve), high LS (>9.6 kPa), and high FIB-4 (>3.25), and vari-
ables at 4 weeks, such as high bilirubin, low albumin, low platelet 
count, and APRI and FIB-4 above each cutoff, showed significant 
association with ETR and SVR12 achievement (all P<0.05) (Sup-
plementary Table 5). Multivariate analyses at each time point 
based on these variables were subsequently performed (Table 2). 
At baseline, high FIB-4 (>3.25) (OR, 0.356; P=0.025) showed re-
versed association with ETR and SVR12 achievement. At 4 weeks 
of treatment, non-invasive fibrosis scoring, such as APRI >0.7 (OR, 
0.248), APRI >1.0 (OR, 0.283), and FIB-4 >3.25 (OR, 0.263) 
showed reversed association with ETR and SVR12 achievement, 
with serum albumin below 3.5 g/dL (all P<0.05).
AEs during antiviral therapy
During 12 weeks of antiviral therapy, the most common AEs 
were headache, fatigue, abdominal discomfort, and skin rash, 
which occurred in 472 (9.4%), 311 (6.2%), 295 (5.9%), and 141 
patients (2.8%). There was no difference in AE development be-
tween IFN-experienced and -naïve groups (Table 3).
DISCUSSION
In this real-world cohort study, 12-week treatment with LDV/
SOF (±ribavirin) showed high effectiveness in 5,028 Mongolian 
patients infected with genotype 1 HCV, regardless of previous IFN 
experience. Compared with that in patients with genotype 1b 
(99.6%), SVR rate in genotype 1a was very low (69.6%) compared 
with that in previous studies; however, the number is relatively 
small (n=23; 0.5%). Non-responders (n=20; 0.4%) also experi-
enced reduction of viral load through 12 weeks of treatment with 
LDV/SOF; however, after the EOT, subsequent virologic break-
through occurred in the 20 patients. No serious AE occurred dur-
ing LDV/SOF treatment.
Similar to western guidelines, the recent Asian-Pacific guideline 
is based on the new era of DAAs on HCV treatment.15,16 Many 
DAAs are currently in use, and currently, pangenotypic DAAs such 
as sofosbuvir/velpatasvir and glecaprevir/pibrentasvir tend to be 
increasingly preferred. However, pangenotypic DAAs are not al-
ways affordable in some developing Asian-Pacific countries owing 
to relatively low healthcare budgets and resources. Nevertheless, 
LDV/SOF is a well-known powerful DAA for genotype 1 HCV that 
showed 93% to 100% SVR rate. Recent European and Asian-Pa-
cific guidelines still recommend 8–12 weeks of LDV/SOF for geno-
type 1b and treatment-naïve genotype 1a, 4, 5, and 6.15,16 As this 
study was conducted in conjunction with a drug-producing com-
pany as part of a Mongolian healthcare program from 2016, ap-
provement of the regimen was restricted to 12 weeks of LDV/SOF 
and ribavirin addition for treatment-experienced patients in Mon-
golia.5,6,17,18
To the best of our knowledge, this is the largest real-life study 
for genotype 1 HCV treated with LDV/SOF in a single country. The 
distribution of HCV genotypes was shown to be quite homoge-
neous in Mongolia in a previous study, which revealed that geno-
type 1b accounted for 98.8% of all genotypes in Mongolia.1 In 
this study, which was limited to genotype 1 HCV, 99.5% of pa-
tients had genotype 1b HCV. Such a high proportion of genotype 
Table 3. Adverse events during antiviral therapy
Adverse event All patients (n=5,028) IFN-naïve (n=4,947; 98.4%) IFN-experienced (n=81; 1.6%) P-value
Fatigue 311 (6.2) 306 (6.2) 5 (6.2) >0.999
Headache 472 (9.4) 464 (9.4) 8 (9.9) 0.847 
Abdominal discomfort 295 (5.9) 290 (5.9) 5 (6.2) 0.811 
Rash 141 (2.8) 138 (2.8) 3 (3.7) 0.496 
Dizziness 88 (1.8) 86 (1.7) 2 (2.5) 0.653 
Diarrhea 55 (1.1) 53 (1.1) 2 (2.5) 0.222 
Nausea 52 (1.0) 51 (1.0) 1 (1.2) 0.572 
Anxiety 46 (0.9) 46 (0.9) 0 (0.0) 1.000 
Values are presented as number (%).
IFN, interferon.
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1b in Mongolian patients might be appropriate for LDV/SOF treat-
ment, which showed an even higher overall SVR rate of 99.6% in 
genotype 1 than that in previous clinical trials.15,16
No virologic relapse was observed until 12 weeks after the EOT 
in this study. However, subsequent elevation of viral load was 
shown to be occur in 20 treatment-failure cases. A recent Japa-
nese study suggested factors such as cirrhosis (OR, 4.19; P=0.014) 
and resistance-associated substitutions (RASs) in NS5A at base-
line (OR, 7.78; P<0.001), and other phase II and III trials also 
showed relatively low SVR12 with NS5A RAS (91% compared 
with 99% without NS5A RAS).19,20 In this study, accurate diagno-
sis of cirrhosis using tissue biopsy or sequential LSM was limited, 
and analysis for NS5A RAS was not available. Instead, we used 
non-invasive fibrosis indices, such as APRI and FIB-4, which 
showed significant association with EOT and SVR12 in multivari-
ate analysis. This result may be considered to be related to the 
maintenance of treatment for a relatively long period of time in 
patients with cirrhosis or patients who have failed treatment in 
the existing guidelines, and might be interpreted as using baseline 
or on-treatment non-invasive fibrosis markers that also can pre-
dict the failure of LDV/SOF treatment. In addition, the viral load of 
patients who failed to achieve ETR and SVR decreased during 
treatment, but increased again after treatment. This may be inter-
preted as that additional doses or another DAAs should be con-
sidered for patients with poor response after 12 weeks of treat-
ment.
Serious AE associated with LDV/SOF was not observed. The AE 
profiles in this study were not different from those in previous 
clinical trials. The most frequent AE was headache followed by fa-
tigue, and there was no AE that resulted in dose interruption or 
treatment discontinuation. Consequently, LDV/SOF or LDV/SOF+ 
ribavirin may be safe for genotype 1 HCV-infected patients in real 
practice.
However, there are several limitations in this study. Firstly, LDV/
SOF is not a novel DAA treatment and is already substituted with 
pangenotypic DAAs. Although LDV/SOF treatment is not a novel 
issue, this large-scale cohort study was aimed to show the effica-
cy and safety of an affordable DAA for developing countries such 
as Mongolia. This study could be a good example of successful 
hepatitis C treatment practice in developing countries where 
healthcare budgets are limited. Secondly, serum markers indicat-
ing tumor markers and renal functions were not analyzed. Thirdly, 
long-term SVR and its effect were not analyzed.
In conclusion, our data showed that LDV/SOF (±ribavirin) regi-
men for 12 weeks was highly effective and safe for genotype 1 
HCV-infected patients in the real-world setting, especially in pa-
tients with genotype 1b. Such results might be translated into 
other patients infected with HCV genotype 1 living in other Asian-
Pacific area as a part of worldwide HCV eradication.
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